Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Marra, Alberto M. ; Halank, Michael ; Benjamin, Nicola ; Bossone, Eduardo ; Cittadini, Antonio ; Eichstaedt, Christina A. ; Egenlauf, Benjamin ; Harutyunova, Satenik ; Fischer, Christine ; Gall, Henning ; Ghofrani, Hossein Ardeschir ; Hoeper, Marius M. ; Lange, Tobias J. ; Olsson, Karen M. ; Klose, Hans ; Grünig, Ekkehard

In: Respiratory Research, 19 (2018), Nr. 258. pp. 1-11. ISSN 1465-993X

[img]
Preview
PDF, English - main document
Download (895kB) | Lizenz: Creative Commons LizenzvertragRight ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study) by Marra, Alberto M. ; Halank, Michael ; Benjamin, Nicola ; Bossone, Eduardo ; Cittadini, Antonio ; Eichstaedt, Christina A. ; Egenlauf, Benjamin ; Harutyunova, Satenik ; Fischer, Christine ; Gall, Henning ; Ghofrani, Hossein Ardeschir ; Hoeper, Marius M. ; Lange, Tobias J. ; Olsson, Karen M. ; Klose, Hans ; Grünig, Ekkehard underlies the terms of Creative Commons Attribution 4.0

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with riociguat.

Methods: Patients who started riociguat treatment (1.0–2.5 mg tid) within the trials phase II, PATENT, PATENTplus, EAS, CHEST and continued treatment for 3–12 months were included in this study. Echocardiography was analysed off-line at baseline, after 3, 6 and 12 months by investigators who were blinded to clinical data. Last and baseline observation carried forward method (LOCF, BOCF) were performed as sensitivity analysis.

Results: Seventy-one patients (45% PAH, 55% CTEPH; 53.5% female; 60 ± 13 years, mean pulmonary arterial pressure 46 ± 10 mmHg, mean PVR 700 ± 282dynes·sec·cm-5) were included. After 6 months, RA and RV area, RV thickness tricuspid regurgitation velocity showed a significant reduction. After 12 months, patients receiving riociguat therapy showed a significant reduction in right atrial (− 2.6 ± 4.4 cm2, 95% CI -3.84, − 1.33; p < 0.001, n = 49) and right ventricular (RV) area (− 3.5 ± 5.2 cm2, 95% CI -5.1, − 1.9; p < 0.001; n = 44), RV thickness (− 0.76 ± 2.2 mm, 95% CI -1.55, 0.03; n = 32), and a significant increase in TAPSE (2.95 ± 4.78 mm, 95% CI 1.52, 4.39; n = 45) and RV fractional area change (8.12 ± 8.87 mm, 95% CI 4.61, 11.62; n = 27). Both LOCF and BOCF showed similar results but lower effect sizes.

Conclusion: Patients under long-term treatment with riociguat show significantly reduced right heart size and improved RV function in PAH and CTEPH. Further controlled prospective studies are needed to confirm these results.

Item Type: Article
Journal or Publication Title: Respiratory Research
Volume: 19
Number: 258
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 08 Feb 2019 10:37
Date: 2018
ISSN: 1465-993X
Page Range: pp. 1-11
Faculties / Institutes: Medizinische Fakultät Heidelberg > Institut für Humangenetik
Medizinische Fakultät Heidelberg > Thoraxklinik Heidelberg gGmbH
Subjects: 610 Medical sciences Medicine
Uncontrolled Keywords: Pulmonary hypertension, Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension, Riociguat, Soluble guanylate cyclase stimulator, Right atrial area, Right heart size, Right ventricular function, Echocardiography
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative